Memantine Treatment of Compulsive Buying

NCT00830375 | Completed Phase 2 Results DMC

• 1 other identifier: 0806M37821
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 2

Brief Summary

This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Conditions

Compulsive Buying

Keywords

Buying; Shopping; Impulse Control

Outcome Measures

Primary Outcomes (1)

• Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)

  The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms

  from study start to study end (8-weeks) and is Investigator rated

Study Arms (1)

Memantine

EXPERIMENTAL

10-30mg, memantine

Drug: Memantine

Interventions

Memantine DRUG

10-30mg, by mouth, daily

Also known as: Namenda

Memantine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• men and women age 18-65
• current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)
• buying behavior within 2 weeks prior to enrollment

You may not qualify if:

• infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB
• unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
• history of seizures
• myocardial infarction within 6 months
• current pregnancy or lactation, or inadequate contraception in women of childbearing potential
• a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
• clinically significant suicidality;
• current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence
• lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
• current or recent (past 3 months) DSM-IV substance abuse or dependence;
• positive urine drug screen at screening
• initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
• previous treatment with memantine
• treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

Sponsors & Collaborators

• University of Minnesota: lead

Study Sites (2)

Ambulatory Research Center

Minneapolis, Minnesota, 55454, United States

Location

University of Minnesota

Minneapolis, Minnesota, 55454, United States

Location

Related Links

• Impulse Control Disorders Clinic - University of Minnesota

MeSH Terms

Conditions

Typhus, Endemic Flea-Borne

Interventions

Memantine

Condition Hierarchy (Ancestors)

Rickettsia Infections; Rickettsiaceae Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Vector Borne Diseases

Intervention Hierarchy (Ancestors)

Amantadine; Adamantane; Bridged-Ring Compounds; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Jon E. Grant
• Organization: University of Minnesota

grant045@umn.edu

612-273-9800

Study Officials

• Jon Grant, MD

  University of Minnesota

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2009
• First Posted: January 27, 2009
• Study Start: December 1, 2008
• Primary Completion: August 1, 2010
• Study Completion: August 1, 2010
• Last Updated: July 29, 2019
• Results First Posted: May 4, 2012

Record last verified: 2019-07

Locations

US (2)